CLIA Kit for Serpin B3 (SERPINB3) Homo sapiens (Human) Sandwich CLIA

SCCA1; T4-A; Serpin Peptidase Inhibitor,Clade B(ovalbumin),Member 3; Serpin B3

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Serpin B3 (SERPINB3) Packages (Simulation)
  • CLIA Kit for Serpin B3 (SERPINB3) Packages (Simulation)
  • CLIA Kit for Serpin B3 (SERPINB3) Results demonstration
  • SCB372Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Serpin B3 (SERPINB3) and the recovery rates were calculated by comparing the measured value to the expected amount of Serpin B3 (SERPINB3) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 93-105 101
EDTA plasma(n=5) 85-92 89
heparin plasma(n=5) 88-97 92

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Serpin B3 (SERPINB3) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Serpin B3 (SERPINB3) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Serpin B3 (SERPINB3) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 87-95% 94-103% 93-105% 98-105%
EDTA plasma(n=5) 80-94% 93-102% 86-104% 93-104%
heparin plasma(n=5) 88-101% 78-101% 78-89% 82-99%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Serpin B3 (SERPINB3)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Serpin B3 (SERPINB3). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Serpin B3 (SERPINB3). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Serpin B3 (SERPINB3) level in the sample or standard.;

Citations

  • Susceptibility to COPD: Differential Proteomic Profiling after Acute SmokingPubmed:25036363
  • Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis.pubmed:28766361
  • Combination of serum squamous cell carcinoma antigens 1 and 2 as potential diagnostic marker for sinonasal squamous cell carcinoma and inverted papillomaPubmed: 30376194

Recommend products